B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Dicerna Pharma (DRNA) on May 20 and set a price target of $24. The company’s shares closed yesterday at $11.89.
According to TipRanks.com, Mamtani is a 1-star analyst with an average return of -1.6% and a 43.9% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Madrigal Pharmaceuticals Inc.
Currently, the analyst consensus on Dicerna Pharma is a Strong Buy with an average price target of $21.50, representing an 80.8% upside. In a report issued on May 9, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.98 and a one-year low of $9.31. Currently, Dicerna Pharma has an average volume of 525.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
